RAPT Therapeutics (RAPT) Competitors $0.89 -0.08 (-7.82%) Closing price 04:00 PM EasternExtended Trading$0.89 +0.00 (+0.23%) As of 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RAPT vs. ALT, SANA, MGTX, MAZE, SIGA, ZVRA, SAGE, AMLX, PRTA, and PRTCShould you be buying RAPT Therapeutics stock or one of its competitors? The main competitors of RAPT Therapeutics include Altimmune (ALT), Sana Biotechnology (SANA), MeiraGTx (MGTX), Maze Therapeutics (MAZE), SIGA Technologies (SIGA), Zevra Therapeutics (ZVRA), Sage Therapeutics (SAGE), Amylyx Pharmaceuticals (AMLX), Prothena (PRTA), and PureTech Health (PRTC). These companies are all part of the "pharmaceutical products" industry. RAPT Therapeutics vs. Altimmune Sana Biotechnology MeiraGTx Maze Therapeutics SIGA Technologies Zevra Therapeutics Sage Therapeutics Amylyx Pharmaceuticals Prothena PureTech Health RAPT Therapeutics (NASDAQ:RAPT) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, community ranking, earnings and media sentiment. Which has preferable earnings & valuation, RAPT or ALT? Altimmune has lower revenue, but higher earnings than RAPT Therapeutics. Altimmune is trading at a lower price-to-earnings ratio than RAPT Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRAPT Therapeutics$1.53M76.78-$116.80M-$2.40-0.37Altimmune$20K22,669.41-$88.45M-$1.26-4.44 Does the media refer more to RAPT or ALT? In the previous week, Altimmune had 21 more articles in the media than RAPT Therapeutics. MarketBeat recorded 23 mentions for Altimmune and 2 mentions for RAPT Therapeutics. RAPT Therapeutics' average media sentiment score of 1.50 beat Altimmune's score of 0.84 indicating that RAPT Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RAPT Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Altimmune 8 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is RAPT or ALT more profitable? RAPT Therapeutics has a net margin of 0.00% compared to Altimmune's net margin of -199,076.92%. Altimmune's return on equity of -55.81% beat RAPT Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets RAPT TherapeuticsN/A -89.10% -76.13% Altimmune -199,076.92%-55.81%-50.60% Does the MarketBeat Community believe in RAPT or ALT? RAPT Therapeutics received 29 more outperform votes than Altimmune when rated by MarketBeat users. However, 72.94% of users gave Altimmune an outperform vote while only 63.19% of users gave RAPT Therapeutics an outperform vote. CompanyUnderperformOutperformRAPT TherapeuticsOutperform Votes9163.19% Underperform Votes5336.81% AltimmuneOutperform Votes6272.94% Underperform Votes2327.06% Do institutionals and insiders hold more shares of RAPT or ALT? 99.1% of RAPT Therapeutics shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 2.4% of RAPT Therapeutics shares are held by insiders. Comparatively, 4.1% of Altimmune shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility & risk, RAPT or ALT? RAPT Therapeutics has a beta of -0.04, meaning that its stock price is 104% less volatile than the S&P 500. Comparatively, Altimmune has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Do analysts rate RAPT or ALT? RAPT Therapeutics currently has a consensus target price of $4.00, suggesting a potential upside of 350.45%. Altimmune has a consensus target price of $20.20, suggesting a potential upside of 261.36%. Given RAPT Therapeutics' higher possible upside, equities analysts plainly believe RAPT Therapeutics is more favorable than Altimmune.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RAPT Therapeutics 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17Altimmune 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryAltimmune beats RAPT Therapeutics on 12 of the 19 factors compared between the two stocks. Get RAPT Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RAPT vs. The Competition Export to ExcelMetricRAPT TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$117.47M$6.48B$5.35B$8.38BDividend YieldN/A2.66%5.22%4.10%P/E Ratio-0.328.9226.8419.71Price / Sales76.78250.95391.39116.98Price / CashN/A65.8538.2534.62Price / Book0.216.466.794.50Net Income-$116.80M$143.98M$3.23B$248.18M7 Day Performance18.37%3.04%4.07%1.14%1 Month Performance13.55%7.44%12.52%15.20%1 Year Performance-80.65%-2.46%16.83%6.56% RAPT Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAPTRAPT Therapeutics4.3849 of 5 stars$0.89-7.8%$4.00+350.5%-75.9%$117.47M$1.53M-0.3280Positive NewsGap DownALTAltimmune2.6299 of 5 stars$6.01+7.5%$20.20+236.1%-27.2%$462.85M$20,000.00-3.8850News CoverageAnalyst RevisionGap UpSANASana Biotechnology2.4474 of 5 stars$2.00+9.9%$10.80+440.0%-75.8%$450.95MN/A-1.43380Gap UpHigh Trading VolumeMGTXMeiraGTx4.5792 of 5 stars$5.62+3.7%$24.50+335.9%-0.7%$449.33M$33.28M-4.64300Analyst RevisionMAZEMaze TherapeuticsN/A$10.13+5.3%$25.67+153.4%N/A$443.65M$167.50M0.00121Earnings ReportGap UpSIGASIGA Technologies1.3585 of 5 stars$5.94+4.9%N/A-17.9%$424.36M$138.72M4.9540ZVRAZevra Therapeutics3.2695 of 5 stars$7.75-1.5%$22.29+187.6%+83.6%$423.76M$23.61M-3.9320News CoverageAnalyst RevisionSAGESage Therapeutics3.955 of 5 stars$6.75+2.9%$8.81+30.6%-36.2%$422.69M$47.40M-1.02690Analyst DowngradeAMLXAmylyx Pharmaceuticals3.4725 of 5 stars$4.60-0.2%$9.67+110.1%+200.0%$409.79M$-1,272,000.00-1.20200PRTAProthena3.8653 of 5 stars$7.61+2.4%$51.71+579.6%-67.8%$409.62M$137.94M-3.31130Positive NewsHigh Trading VolumePRTCPureTech Health1.5174 of 5 stars$17.03+1.5%$45.00+164.3%-39.3%$408.92M$4.32M0.00100Gap Up Related Companies and Tools Related Companies Altimmune Competitors Sana Biotechnology Competitors MeiraGTx Competitors Maze Therapeutics Competitors SIGA Technologies Competitors Zevra Therapeutics Competitors Sage Therapeutics Competitors Amylyx Pharmaceuticals Competitors Prothena Competitors PureTech Health Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RAPT) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RAPT Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RAPT Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RAPT Stock Free RAPT Stock Alerts